Comprehensive Stock Comparison
Compare Protagonist Therapeutics, Inc. (PTGX) vs argenx SE (ARGX) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | ARGX | 78.6% revenue growth vs PTGX's -100.0% |
| Value | PTGX | Lower P/E (25.4x vs 25.6x) |
| Stability / Safety | ARGX | Lower D/E ratio (0.7% vs 1.7%) |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | PTGX | +145.0% vs ARGX's +22.8% |
| Efficiency (ROA) | ARGX | 12.9% ROA vs PTGX's -19.5%, ROIC -0.5% vs -21.8% |
Who Each Stock Is For
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Protagonist Therapeutics is a clinical-stage biopharmaceutical company developing peptide-based drugs for blood disorders and inflammatory diseases. It generates revenue primarily through collaboration agreements — notably with Janssen Biotech — and has no commercial products yet, relying on milestone payments and potential future royalties. The company's key advantage is its proprietary peptide discovery platform that enables the development of orally available peptide therapeutics, a challenging area in drug development.
argenx is a biotechnology company that develops antibody-based therapies for autoimmune diseases. It generates nearly all its revenue from VYVGART — its FcRn blocker for conditions like myasthenia gravis — with additional income from partnerships and licensing. The company's key advantage is its proprietary antibody engineering platform that creates differentiated therapies with potentially better safety and efficacy profiles.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
PTGX leads in 3 of 6 categories (Valuation Metrics, Total Returns). ARGX leads in 2 (Financial Metrics, Profitability & Efficiency).
Financial Metrics (TTM)
ARGX and PTGX operate at a comparable scale, with $4.0B and $0 in trailing revenue. On growth, ARGX holds the edge at +5.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | PTGXProtagonist Thera… | ARGXargenx SE |
|---|---|---|
| RevenueTrailing 12 months | $0 | $4.0B |
| EBITDAEarnings before interest/tax | -$158M | $95M |
| Net IncomeAfter-tax profit | -$130M | $923M |
| Free Cash FlowCash after capex | $58M | $213M |
| Gross MarginGross profit ÷ Revenue | — | +75.5% |
| Operating MarginEBIT ÷ Revenue | — | -1.0% |
| Net MarginNet income ÷ Revenue | — | +23.3% |
| FCF MarginFCF ÷ Revenue | — | +5.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | -122.6% | +5.1% |
| EPS Growth (YoY)Latest quarter vs prior year | -134.8% | +12.6% |
Valuation Metrics
| Metric | PTGXProtagonist Thera… | ARGXargenx SE |
|---|---|---|
| Market CapShares × price | $5.8B | $47.5B |
| Enterprise ValueMkt cap + debt − cash | $5.6B | $46.0B |
| Trailing P/EPrice ÷ TTM EPS | -44.92x | 60.01x |
| Forward P/EPrice ÷ next-FY EPS est. | 25.45x | 25.57x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 21.67x |
| Price / BookPrice ÷ Book value/share | 9.52x | 9.09x |
| Price / FCFMarket cap ÷ FCF | 99.91x | — |
Profitability & Efficiency
ARGX delivers a 15.1% return on equity — every $100 of shareholder capital generates $15 in annual profit, vs $-21 for PTGX. ARGX carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to PTGX's 0.02x. On the Piotroski fundamental quality scale (0–9), PTGX scores 4/9 vs ARGX's 3/9, reflecting mixed financial health.
| Metric | PTGXProtagonist Thera… | ARGXargenx SE |
|---|---|---|
| ROE (TTM)Return on equity | -21.2% | +15.1% |
| ROA (TTM)Return on assets | -19.5% | +12.9% |
| ROICReturn on invested capital | -21.8% | -0.5% |
| ROCEReturn on capital employed | -24.0% | -0.4% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 3 |
| Debt / EquityFinancial leverage | 0.02x | 0.01x |
| Net DebtTotal debt minus cash | -$118M | -$1.5B |
| Cash & Equiv.Liquid assets | $128M | $1.5B |
| Total DebtShort + long-term debt | $10M | $39M |
| Interest CoverageEBIT ÷ Interest expense | — | 166.64x |
Total Returns (with DRIP)
A $10,000 investment in PTGX five years ago would be worth $34,422 today (with dividends reinvested), compared to $22,521 for ARGX. Over the past 12 months, PTGX leads with a +145.0% total return vs ARGX's +22.8%. The 3-year compound annual growth rate (CAGR) favors PTGX at 78.4% vs ARGX's 28.0% — a key indicator of consistent wealth creation.
| Metric | PTGXProtagonist Thera… | ARGXargenx SE |
|---|---|---|
| YTD ReturnYear-to-date | +5.6% | -8.7% |
| 1-Year ReturnPast 12 months | +145.0% | +22.8% |
| 3-Year ReturnCumulative with dividends | +467.7% | +109.5% |
| 5-Year ReturnCumulative with dividends | +244.2% | +125.2% |
| 10-Year ReturnCumulative with dividends | +687.0% | +3234.4% |
| CAGR (3Y)Annualised 3-year return | +78.4% | +28.0% |
Risk & Volatility
PTGX is the less volatile stock with a -0.11 beta — it tends to amplify market swings less than ARGX's 0.44 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PTGX currently trades 95.4% from its 52-week high vs ARGX's 82.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | PTGXProtagonist Thera… | ARGXargenx SE |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -0.11x | 0.44x |
| 52-Week HighHighest price in past year | $96.54 | $934.62 |
| 52-Week LowLowest price in past year | $35.97 | $510.06 |
| % of 52W HighCurrent price vs 52-week peak | +95.4% | +82.1% |
| RSI (14)Momentum oscillator 0–100 | 62.7 | 33.9 |
| Avg Volume (50D)Average daily shares traded | 594K | 301K |
Analyst Outlook
Wall Street rates PTGX as "Buy" and ARGX as "Buy". Consensus price targets imply 33.9% upside for ARGX (target: $1027) vs 21.4% for PTGX (target: $112).
| Metric | PTGXProtagonist Thera… | ARGXargenx SE |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $111.75 | $1026.71 |
| # AnalystsCovering analysts | 24 | 35 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| Protagonist Therape… (PTGX) | 100 | 1,048.61 | +948.6% |
| argenx SE (ARGX) | 100 | 564.69 | +464.7% |
Protagonist Therape… (PTGX) returned +244% over 5 years vs argenx SE (ARGX)'s +125%. A $10,000 investment in PTGX 5 years ago would be worth $34,422 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Protagonist Therape… (PTGX) | $0.00 | $0.00 | — |
| argenx SE (ARGX) | $15M | $2.2B | +14054.3% |
Protagonist Therapeutics, Inc.'s revenue grew from $0M (2016) to $0M (2025) — a 0.0% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Protagonist Therape… (PTGX) | -184.2% | 63.3% | +134.4% |
| argenx SE (ARGX) | -2.2% | 38.0% | +1802.4% |
argenx SE's net margin went from -2% (2015) to 38% (2024).
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Protagonist Therape… (PTGX) | -5.72 | -2.05 | +64.2% |
| argenx SE (ARGX) | -1.2 | 12.78 | +1165.0% |
Protagonist Therapeutics, Inc.'s EPS grew from $-5.72 (2016) to $-2.05 (2025).
Chart 5Free Cash Flow — 5 Years
Protagonist Therapeutics, Inc. generated $58M FCF in 2025 (+153% vs 2021). argenx SE generated $-151M FCF in 2024 (+79% vs 2021).
PTGX vs ARGX: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is PTGX or ARGX a better buy right now?
argenx SE (ARGX) offers the better valuation at 60.0x trailing P/E (25.6x forward), making it the more compelling value choice. Analysts rate Protagonist Therapeutics, Inc. (PTGX) a "Buy" — based on 24 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — PTGX or ARGX?
On forward P/E, Protagonist Therapeutics, Inc. is actually cheaper at 25.4x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — PTGX or ARGX?
Over the past 5 years, Protagonist Therapeutics, Inc. (PTGX) delivered a total return of +244.2%, compared to +125.2% for argenx SE (ARGX). A $10,000 investment in PTGX five years ago would be worth approximately $34K today (assuming dividends reinvested). Over 10 years, the gap is even starker: ARGX returned +32.3% versus PTGX's +687.0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — PTGX or ARGX?
By beta (market sensitivity over 5 years), Protagonist Therapeutics, Inc. (PTGX) is the lower-risk stock at -0.11β versus argenx SE's 0.44β — meaning ARGX is approximately -502% more volatile than PTGX relative to the S&P 500. On balance sheet safety, argenx SE (ARGX) carries a lower debt/equity ratio of 1% versus 2% for Protagonist Therapeutics, Inc. — giving it more financial flexibility in a downturn.
05Which has better profit margins — PTGX or ARGX?
argenx SE (ARGX) is the more profitable company, earning 38.0% net margin versus 0.0% for Protagonist Therapeutics, Inc. — meaning it keeps 38.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PTGX leads at 0.0% versus -1.0% for ARGX. At the gross margin level — before operating expenses — ARGX leads at 89.6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is PTGX or ARGX more undervalued right now?
On forward earnings alone, Protagonist Therapeutics, Inc. (PTGX) trades at 25.4x forward P/E versus 25.6x for argenx SE — 0.1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ARGX: 33.9% to $1026.71.
07Which pays a better dividend — PTGX or ARGX?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is PTGX or ARGX better for a retirement portfolio?
For long-horizon retirement investors, Protagonist Therapeutics, Inc. (PTGX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.11), +687.0% 10Y return). Both have compounded well over 10 years (PTGX: +687.0%, ARGX: +32.3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between PTGX and ARGX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.